Fabiane Maria de Almeida Ferreira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fabiane Maria de Almeida Ferreira has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Angela Pires Brandao
Núcleo de Tuberculose e Micobacterioses, Centro de Bacteriologia, Instituto Adolfo Lutz (IAL), São Paulo 01246-000, Brazil
3 shared publications - Erica Chimara
Instituto Adolfo Lutz
3 shared publications - Juliana Maira Watanabe Pinhata
Instituto Adolfo Lutz, Brasil
3 shared publications - Lucilaine Ferrazoli
Instituto Adolfo Lutz, Brasil
3 shared publications - Rosangela Siqueira de Oliveira
Instituto Adolfo Lutz
3 shared publications - Fernanda Cristina dos Santos Simeao
Instituto Adolfo Lutz
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2470
Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting
Drug-resistant tuberculosis (DR-TB) threatens global TB control. We investigated the prevalence and molecular characteristics of second-line drug resistance among rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis complex (MTBC) isolates in São Paulo, Brazil, using the MTBDRsl v. 2.0 line-probe assay. MTBC isolates RIF- and/or INH-resistant by GenoType MTBDRplus or phenotypic testing (2019–2021) were subsequently tested by MTBDRsl for fluoroquinolone (FQ) and injectable drugs (capreomycin, amikacin, kanamycin) resistance. Isolates with inferred mutations underwent Sanger sequencing. Of 13,557 isolates, 728 (5.4%) were RIF- and/or INH-resistant (297 INH-R, 235 RIF-R, 196 MDR). Among them, 623 (85.6%) were tested by MTBDRsl; 582 (93.4%) showed no additional resistance, while 41 (6.6%) carried mutations. FQ resistance was detected in 38 isolates (92.7%), mostly in gyrA (n = 35). Three isolates with gyrB mutations were wild-type by sequencing. Two MDR isolates harbored the rrs a1401g mutation, and one also harbored gyrA D94G. Sequencing confirmed resistance in 38 of 41 isolates. Most MDR strains with second-line mutations (n = 32/33; 97%) were pre-XDR. Affected patients were predominantly male (68.4%), with pulmonary TB (92.1%), and unfavorable outcomes (39.5%). Second-line resistance prevalence was low overall, but FQ resistance was high among MDR isolates. Findings support integrating molecular and sequencing-based tools for accurate detection and management of DR-TB.
- 29 October 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (11) , 2470
Open AccessFluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting
Drug-resistant tuberculosis (DR-TB) threatens global TB control. We investigated the prevalence and molecular characteristics of second-line drug resistance among rifampicin (RIF)- and/or isoniazid (INH)-resistant Mycobacterium tuberculosis complex (MTBC) isolates in São Paulo, Brazil, using the MTBDRsl v. 2.0 line-probe assay. MTBC isolates RIF- and/or INH-resistant by GenoType MTBDRplus or phenotypic testing (2019–2021) were subsequently tested by MTBDRsl for fluoroquinolone (FQ) and injectable drugs (capreomycin, amikacin, kanamycin) resistance. Isolates with inferred mutations underwent Sanger sequencing. Of 13,557 isolates, 728 (5.4%) were RIF- and/or INH-resistant (297 INH-R, 235 RIF-R, 196 MDR). Among them, 623 (85.6%) were tested by MTBDRsl; 582 (93.4%) showed no additional resistance, while 41 (6.6%) carried mutations. FQ resistance was detected in 38 isolates (92.7%), mostly in gyrA (n = 35). Three isolates with gyrB mutations were wild-type by sequencing. Two MDR isolates harbored the rrs a1401g mutation, and one also harbored gyrA D94G. Sequencing confirmed resistance in 38 of 41 isolates. Most MDR strains with second-line mutations (n = 32/33; 97%) were pre-XDR. Affected patients were predominantly male (68.4%), with pulmonary TB (92.1%), and unfavorable outcomes (39.5%). Second-line resistance prevalence was low overall, but FQ resistance was high among MDR isolates. Findings support integrating molecular and sequencing-based tools for accurate detection and management of DR-TB.
- Open Access
Off-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in a high-volume reference laboratory
Drug-resistant tuberculosis (TB) remains a major global health concern. Multidrug-resistant TB is defined by resistance to at least rifampicin (RIF) and isoniazid (INH), the two key drugs used in TB treatment. The BD MAX™ Multi-Drug Resistant Tuberculosis (BD MAX) assay is a fully automated real-time PCR platform, recommended by the World Health Organization for the initial diagnosis of TB and RIF and INH resistance (RIF-R and INH-R) directly from pulmonary clinical samples. This study aimed to assess the off-label performance of BD MAX in clinical M. tuberculosis complex (MTBC) isolates under routine laboratory conditions. The assay was first validated using non-tuberculous mycobacteria (NTM) and MTBC isolates with known mutations. For real-world validation, it was compared to the GenoType MTBDR plus by testing 1,440 clinical isolates prospectively. The BD MAX assay correctly excluded MTBC from all NTM cultures. Among MTBC isolates with known mutations, it identified 19 of 20 RIF-R isolates and 14 of 15 INH-R isolates. In prospective testing, BD MAX achieved 99.8% sensitivity (1,406/1,409), 100% specificity (31/31), and 99.8% (1,437/1,440) overall accuracy for MTBC detection. For drug resistance detection, it showed 95.2% (40/42) concordance for RIF, 96.8% (30/31) for INH and 81.3% (13/16) for MDR when compared to MTBDR plus . Discrepancies between MTBDR plus and BD MAX included heteroresistant cases and unreportable resistance results by BD MAX due to infrequent mutations or low bacterial load. Overall, this study confirms BD MAX as an accurate and reliable tool for MTBC detection and drug resistance profiling in clinical isolates in high-volume TB laboratories. Importance: This study highlights the importance of the BD MAX™ Multi-Drug Resistant Tuberculosis assay (BD MAX) applied in clinical isolates for the detection of multidrug-resistant tuberculosis (MDR-TB), i.e., Mycobacterium tuberculosis resistance to rifampicin and isoniazid. TB is a global health issue, and drug-resistant TB makes treatment more difficult, favoring transmission and disease amplification. The BD MAX platform offers a faster and more automated way to detect TB and drug resistance. The study showed that BD MAX applied off-label in clinical isolates accurately identified TB and resistance to rifampicin and isoniazid, with results comparable to the widely used line probe assay. This is significant in a high-volume laboratory because it is simpler and more rapid than the line probe assay. BD MAX showed some limitations, especially in detecting rare mutations and in cases of low bacteria levels. Overall, this tool could improve TB care, especially in high-volume laboratories.
Open AccessOff-label evaluation of the BD MAX MDR-TB assay for rapid diagnosis of rifampicin and isoniazid resistance of Mycobacterium tuberculosis clinical isolates in a high-volume reference laboratory
Drug-resistant tuberculosis (TB) remains a major global health concern. Multidrug-resistant TB is defined by resistance to at least rifampicin (RIF) and isoniazid (INH), the two key drugs used in TB treatment. The BD MAX™ Multi-Drug Resistant Tuberculosis (BD MAX) assay is a fully automated real-time PCR platform, recommended by the World Health Organization for the initial diagnosis of TB and RIF and INH resistance (RIF-R and INH-R) directly from pulmonary clinical samples. This study aimed to assess the off-label performance of BD MAX in clinical M. tuberculosis complex (MTBC) isolates under routine laboratory conditions. The assay was first validated using non-tuberculous mycobacteria (NTM) and MTBC isolates with known mutations. For real-world validation, it was compared to the GenoType MTBDR plus by testing 1,440 clinical isolates prospectively. The BD MAX assay correctly excluded MTBC from all NTM cultures. Among MTBC isolates with known mutations, it identified 19 of 20 RIF-R isolates and 14 of 15 INH-R isolates. In prospective testing, BD MAX achieved 99.8% sensitivity (1,406/1,409), 100% specificity (31/31), and 99.8% (1,437/1,440) overall accuracy for MTBC detection. For drug resistance detection, it showed 95.2% (40/42) concordance for RIF, 96.8% (30/31) for INH and 81.3% (13/16) for MDR when compared to MTBDR plus . Discrepancies between MTBDR plus and BD MAX included heteroresistant cases and unreportable resistance results by BD MAX due to infrequent mutations or low bacterial load. Overall, this study confirms BD MAX as an accurate and reliable tool for MTBC detection and drug resistance profiling in clinical isolates in high-volume TB laboratories. Importance: This study highlights the importance of the BD MAX™ Multi-Drug Resistant Tuberculosis assay (BD MAX) applied in clinical isolates for the detection of multidrug-resistant tuberculosis (MDR-TB), i.e., Mycobacterium tuberculosis resistance to rifampicin and isoniazid. TB is a global health issue, and drug-resistant TB makes treatment more difficult, favoring transmission and disease amplification. The BD MAX platform offers a faster and more automated way to detect TB and drug resistance. The study showed that BD MAX applied off-label in clinical isolates accurately identified TB and resistance to rifampicin and isoniazid, with results comparable to the widely used line probe assay. This is significant in a high-volume laboratory because it is simpler and more rapid than the line probe assay. BD MAX showed some limitations, especially in detecting rare mutations and in cases of low bacteria levels. Overall, this tool could improve TB care, especially in high-volume laboratories.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 58, e01842025
Comprehensive analysis of mutations associated with rifampicin- and isoniazid-resistant tuberculosis in a high-burden setting
Background: In this study, we aimed to describe the mutations associated with first-line drug resistance in Mycobacterium tuberculosis complex (MTBC) isolates from São Paulo, Brazil, between 2019 and 2021. Methods: Mutations in the coding regions of rpoB and katG genes and in the promoter region of the inhA gene in MTBC clinical isolates were detected using the GenoType MTBDRplus assay (LPA). All mutations inferred by LPA were sequenced. Results: Of the 13,489 MTBC isolates with valid LPA results, 657 (4.9%) harbored mutations. The overall prevalence rates of rifampicin-resistant (RIF-R) tuberculosis (TB), isoniazid-resistant (INH-R) TB, and multidrug-resistant (MDR) TB were 1.5, 2.0, and 1.2%, respectively. A significant proportion of RIF-R isolates presented inferred rpoB mutations (89.1%), most of which were the borderline H445N mutation. The inhA promoter C-15T mutation was predominant among the INH-R isolates (52.8%). Most MDR isolates presented rpoB S450L + katG S315T1 mutations. Gene sequencing identified mutations not included in the catalogue of mutations published by the World Health Organization. Phenotypic drug susceptibility testing on isolates with inferred rpoB mutations revealed that the 0.5 µg/mL critical concentration of RIF failed to detect most borderline mutations when using the BACTEC MGIT 960 system. Conclusions: These findings emphasize the need for continuous surveillance and the integration of molecular and phenotypic methods to ensure an accurate detection and management of drug-resistant TB in high-burden settings.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Revista da Sociedade Brasileira de Medicina Tropical
- Vol. 58, e01842025
Open AccessComprehensive analysis of mutations associated with rifampicin- and isoniazid-resistant tuberculosis in a high-burden setting
Background: In this study, we aimed to describe the mutations associated with first-line drug resistance in Mycobacterium tuberculosis complex (MTBC) isolates from São Paulo, Brazil, between 2019 and 2021. Methods: Mutations in the coding regions of rpoB and katG genes and in the promoter region of the inhA gene in MTBC clinical isolates were detected using the GenoType MTBDRplus assay (LPA). All mutations inferred by LPA were sequenced. Results: Of the 13,489 MTBC isolates with valid LPA results, 657 (4.9%) harbored mutations. The overall prevalence rates of rifampicin-resistant (RIF-R) tuberculosis (TB), isoniazid-resistant (INH-R) TB, and multidrug-resistant (MDR) TB were 1.5, 2.0, and 1.2%, respectively. A significant proportion of RIF-R isolates presented inferred rpoB mutations (89.1%), most of which were the borderline H445N mutation. The inhA promoter C-15T mutation was predominant among the INH-R isolates (52.8%). Most MDR isolates presented rpoB S450L + katG S315T1 mutations. Gene sequencing identified mutations not included in the catalogue of mutations published by the World Health Organization. Phenotypic drug susceptibility testing on isolates with inferred rpoB mutations revealed that the 0.5 µg/mL critical concentration of RIF failed to detect most borderline mutations when using the BACTEC MGIT 960 system. Conclusions: These findings emphasize the need for continuous surveillance and the integration of molecular and phenotypic methods to ensure an accurate detection and management of drug-resistant TB in high-burden settings.